Business Wire

NetJets Announces Collaboration With Acclaimed Artist Silvère Jarrosson

21.5.2024 16:10:00 EEST | Business Wire | Press release

Share

For the 23rd consecutive year, NetJets, the global leader in private aviation, proudly announces its partnership with Art Basel. To highlight its commitment to the arts, NetJets will collaborate with French abstract artist Silvère Jarrosson to create a new art collection exclusively for NetJets that will be displayed at the Art Basel shows in Basel, Paris and Miami Beach.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240521442854/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Silvère Jarrosson, credit Julien Benhamou

Born and raised in Paris, Jarrosson trained as a ballet dancer at the renowned Opera National de Paris at only 10 years old but transitioned into abstract painting a decade ago. His background in ballet is seen throughout his motion and fluidity while creating his works of art. Represented by contemporary art agency Studio Artera in Paris, Jarrosson is known for using his whole body to make his art – as he moves or ‘dances’ with the canvas to create his signature acrylic pieces.

At only 31 years of age, Jarrosson has received widespread praise and has had his work showcased globally. His art is featured in prestigious institutions such as the Villa Medici in Rome, the Unterlinden Museum in Colmar, the Lambert Collection in Avignon, the Crédit du Nord Collection, the Mobilier National and the Opera National de Paris, among others.

Jarrosson’s project created for NetJets, entitled “Inner Horizons”, offers Owners – the individuals and businesses who are clients of NetJets’ private jet ownership model – captivating insight into his world of poetic immersion, where his spectators become part of the creative inspiration for his shows and projects. His work will be featured in NetJets' exclusive area within the Collectors Lounge. Accessible only by Owners, it will offer a secluded space for guests to enjoy hospitality throughout the show week of Art Basel in Basel. The show aims to merge external travel experiences made possible by NetJets with inner travel experiences created by Jarrosson’s art.

Patrick Gallagher, President of Sales, Marketing & Service, commented: “We are delighted with this partnership. We admire the synergy from the movement Silvère uses to create his art pieces. His beautiful artwork truly moves observers who watch him paint. Despite coming from different industries, we align in our passion to both create and capture exceptional experiences for others. As many of our Owners are deeply interested in fine art, we believe this partnership will be both inspiring and exciting as Silvère’s career continues to flourish.”

Globally recognised for its revolutionary shared ownership business model, NetJets’ impeccable reputation spans more than 60 years and has reshaped how people fly private. NetJets proudly maintains and operates over 1,000 aircraft, grants access to more than 5,000 airports and employs over 8,300 private aviation professionals to deliver outstanding service.

About NetJets

Originally incorporated in 1964 as Executive Jet Airways, NetJets has been setting – and exceeding – industry standards for over 60 years. Today, NetJets is proud to be a Berkshire Hathaway company known for its unwavering commitment to safety and service. NetJets’ portfolio of distinctive companies, encompassing NetJets, Executive Jet Management, QS Partners and QS Security, offers a variety of customisable travel solutions, including shared ownership, lease and jet card options, aircraft management, private jet chartering, brokerage and acquisition services and specialised security services. This comprehensive suite of solutions is why so many of the world’s most discerning travellers choose NetJets generation after generation. It is also because NetJets has the largest, most diverse private jet fleet in the world, which grants anytime access to even the most remote destinations across the globe. To learn more about the leader in private aviation, visit netjets.com today.

About Studio Artera

Studio Artera is an art and talent agency based in Paris that supports the finest visual artists.

We represent artists and integrate art in all contexts by creating meaningful artistic collaborations with brands, companies, cultural institutions, and cities. Driven by the desire to reach an ever-wider audience through art, we build artistic narratives with our clients to inspire millions of people around the world.

Clients of Studio Artera include Louis Vuitton, Prada, Levi’s, Bombay Sapphire, the Hoxton Group, the City of Paris, Château Charmail, and Viva Technology.

To learn more about us, please visit www.studioartera.com

About Art Basel

Founded in 1970 by gallerists from Basel, Art Basel today stages the world’s premier art shows for Modern and contemporary art, sited in Basel, Miami Beach, Hong Kong, and Paris. Defined by its host city and region, each show is unique, which is reflected in its participating galleries, artworks presented, and the content of parallel programming produced in collaboration with local institutions for each edition. Art Basel’s engagement has expanded beyond art fairs through new digital platforms and initiatives such as the Art Basel and UBS Global Art Market Report. Art Basel’s Global Media Partner is The Financial Times. For further information, please visit artbasel.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact:
NetJets/NetJets Europe
pressnetjets@kwtglobal.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye